Reproductive biomedicine online最新文献

{"title":"Ultra-fast vitrification and rapid elution of human oocytes: Part II – verification of blastocyst development from mature oocytes","authors":"Kathryn Wozniak ,&nbsp;Ryan Reichelderfer ,&nbsp;Seyed Ghaemi ,&nbsp;Danielle Hupp ,&nbsp;Peter Fuzesi ,&nbsp;Guy Ringler ,&nbsp;Richard P. Marrs ,&nbsp;Mitchel C. Schiewe","doi":"10.1016/j.rbmo.2024.104690","DOIUrl":"10.1016/j.rbmo.2024.104690","url":null,"abstract":"<div><h3>Research question</h3><div>Will ultra-fast vitrification (UFV) and rapid elution of mature human oocytes retain the reliable, high survival rates and meiotic spindle normality seen in the germinal vesicle model, and will these oocytes maintain their developmental competence to form blastocyst-stage embryos following artificial oocyte activation (AOA)?</div></div><div><h3>Design</h3><div>Conventional vitrification treatment was compared with UFV treatment in mature, germinal-vesicle-derived oocytes (Phase 2, Expt. 2, <em>n</em> = 50) and substandard donor oocytes, metaphase I–metaphase II (MII) oocytes and poor-quality MII oocytes (<em>n</em> = 222). Post-warming survival, the integrity of the meiotic spindle and AOA-related development were assessed.</div></div><div><h3>Results</h3><div>Overall survival rates were higher (<em>P</em> = 0.003) for UFV/rapid elution treatment (94–100%, mean = 98%) compared with conventional vitrification/control dilution treatment (80–90%, mean = 83.3%). MII oocytes derived from immature germinal vesicles following conventional vitrification/control dilution or UFV/rapid elution treatments proved to be capable of activated development (54–71% cleavage rate), with four blastocysts produced. AOA treatment with DMAP exposure yielded optimal activated development. When vitrifying mature oocytes, both UFV and conventional vitrification treatments exhibited normal activated development and blastocyst production (34.9% and 31.7%, respectively).</div></div><div><h3>Conclusions</h3><div>Considering that oocyte freezing was deemed non-experimental based primarily on healthy live births from frozen-oocyte-derived embryo transfer the validation of normal blastocyst formation using the novel UFV approach is a critical accomplishment. The UFV method for oocyte cryopreservation represents a strategic deviation from traditional semi-equilibration vitrification protocols. UFV is a more time-efficient approach that consistently yields a higher survival rate, and thus has the potential to create more embryos. These findings justify proceeding with strategic clinical trial applications.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104690"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Front Matter - Continued TOC","authors":"","doi":"10.1016/S1472-6483(24)00900-3","DOIUrl":"10.1016/S1472-6483(24)00900-3","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104711"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ultra-fast vitrification and rapid elution of human oocytes: part I. germinal vesicle model validation","authors":"Mitchel C. Schiewe ,&nbsp;Ryan Reichelderfer ,&nbsp;Kathryn Wozniak ,&nbsp;Claudia De Romana ,&nbsp;Melanie Nordbak ,&nbsp;Kelly Baek ,&nbsp;Karine Chung","doi":"10.1016/j.rbmo.2024.104691","DOIUrl":"10.1016/j.rbmo.2024.104691","url":null,"abstract":"<div><h3>Research question</h3><div>Can GV-oocytes serve as an effective model to test the efficacy of ultra-fast vitrification (UFV)/ rapid elution (RE) treatments to support reliable, high survival rates and sustained functionality?</div></div><div><h3>Design</h3><div>Prospective pilot cohort studies were performed to investigate the feasibility of non-equilibration, UFV to sustain cellular integrity and development in contrast to control vitrification (CV: 10-15min ES/ 1min VS). In Phase 1, we applied a 2 × 2 factorial design (n=25-30 eggs/group) to evaluate post-warming dilution treatments: conventional multi-step (CD) versus rapid elution (RE; one-step), including an apriori fresh egg control group. Phase 1/2 focused on survival and maturation assessments, including meiotic spindle formation (Phase 2).</div></div><div><h3>Results</h3><div>The survival of EG/DMSO treated UFV oocytes in Phase 1 and 2 was not different to spontaneous degeneration seen in the fresh IVM control groups (3.2%) but was higher than CV treated oocytes immediately post-warming (p&lt;0.03). Of the intact GVs, no difference in IVM-MII development was detected (52.6 -58.3%) at +48h IVM across all groups. Meiotic spindle integrity of MII oocytes was normal in all treatment groups.</div></div><div><h3>Conclusions</h3><div>As originally reported by Gallardo (2019), non-equilibrated dehydrated human oocytes can effectively vitrify after UFV/CD treatment. We further verified the resiliency of oocytes to withstand RE treatment and continue to develop normally, like fresh GV-matured oocytes. Furthermore, we confirmed that the meiotic spindle formation and density of UFV/RE-treated GV oocytes was similar to fresh controls. Overall, the GV-model proved to be a useful resource to substantiate the promising potential of UFV technology to reliably achieve high survival and normal developmental competence in a more time efficient manner.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104691"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142605511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inside Front Cover - Affiliations and First page of TOC","authors":"","doi":"10.1016/S1472-6483(24)00899-X","DOIUrl":"10.1016/S1472-6483(24)00899-X","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104710"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143128760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sir Robert Edwards: from the science of human conception to the reality of IVF birth","authors":"Kamal K. Ahuja","doi":"10.1016/j.rbmo.2024.104478","DOIUrl":"10.1016/j.rbmo.2024.104478","url":null,"abstract":"<div><div>With a new Netflix film <em>Joy</em> telling the dramatic story of IVF, Dr Kamal Ahuja recalls the inspirational role that the late Sir Robert Edwards played in his own career and in the foundation of the London Women's Clinic.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104478"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142473600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outside Back Cover - Editorial Board","authors":"","doi":"10.1016/S1472-6483(24)00912-X","DOIUrl":"10.1016/S1472-6483(24)00912-X","url":null,"abstract":"","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"49 6","pages":"Article 104723"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143136242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late maturing oocyte rescue in poor-prognosis patients: delayed intracytoplasmic sperm injection results in more viable embryos","authors":"Balsam Al Hashimi ,&nbsp;Simon C. Harvey ,&nbsp;Katie E. Harvey ,&nbsp;Elena Linara-Demakakou ,&nbsp;Darren K. Griffin ,&nbsp;Kamal Ahuja ,&nbsp;Nick Macklon","doi":"10.1016/j.rbmo.2024.104735","DOIUrl":"10.1016/j.rbmo.2024.104735","url":null,"abstract":"<div><h3>Research question</h3><div>Can delayed intracytoplasmic sperm injection (DICSI) in late maturing oocytes improve fertilization, blastocyst formation, pregnancy and live birth rates for poor-prognosis patients?</div></div><div><h3>Design</h3><div>Retrospective analysis of 2243 oocytes from 250 poor-prognosis patients who underwent 311 assisted reproductive technology (ART) cycles. Patients were offered DICSI to increase the number of embryos available for testing when over 50% of oocytes collected were immature on day 0, less than 50% of the injected oocytes were fertilized on day 1 or when patients were undergoing preimplantation genetic testing for aneuploidy.</div></div><div><h3>Results</h3><div>Fertilization and blastulation rates differed depending on the original assessment of the oocyte maturation stage. Euploidy rate did not differ between blastocysts derived from fertilized oocytes originally assessed as metaphase I (MI) or metaphase II (MII). A transferred blastocyst derived from a matured oocyte originally assessed as MI was as likely to result in a live birth as one from a MII oocyte. No differences in delivery method, gestation period or birth weight were found between intracytoplasmic sperm injection and DICSI. As a result of DICSI, at least 27 cycles (8.7%), which would have otherwise been unproductive, resulted in live births, with five ongoing pregnancies.</div></div><div><h3>Conclusions</h3><div>Both MI and germinal vesicle oocytes can complete maturation <em>in vitro</em>. Blastocysts produced from these are likely to be chromosomally normal compared with oocytes originally assessed as MII, and result in similar live birth rates. With no differences in birth outcomes, and DICSI increasing overall ART cycle success, this approach has value for poor-prognosis patients.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"50 5","pages":"Article 104735"},"PeriodicalIF":3.7,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143724235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What to expect from a ‘standard vaginal progesterone regimen’ in hormone replacement therapy frozen embryo transfer (HRT-FET) – a PRISMA review and meta-analysis","authors":"B. Alsbjerg ,&nbsp;P. Humaidan","doi":"10.1016/j.rbmo.2024.104736","DOIUrl":"10.1016/j.rbmo.2024.104736","url":null,"abstract":"<div><div>A mid-luteal serum progesterone concentration below 9–11 ng/ml has been shown to have a negative impact on reproductive outcomes in hormone replacement therapy frozen embryo transfer (HRT-FET), and as no corpus luteum is present, this concentration reflects the absorption of the progesterone products administered. However, the composition and dosing regimens of vaginal products vary. In total, 24 studies were included in this review, selected according to the following criteria: the use of vaginal progesterone products, with serum progesterone concentration and regimens reported; the absence of additional progesterone or progestin treatments; and the use of both prospective and retrospective study designs. Abstracts and full texts published in languages other than English were excluded. A random-effects proportional meta-analysis of five different vaginal micronized progesterone products was performed, including a total of 11,014 patients. Significant differences were found when comparing Cyclogest (800 mg) with Crinone (180 mg or 270 mg) (<em>P</em> = 0.01); Cyclogest (800 mg) with Utrogestan/Progestan (600 mg or 800 mg) (<em>P</em> = 0.03); and Cyclogest (800 mg) with Lutinus (300 mg) (<em>P</em> = 0.01). However, no significant differences were identified between products with an equivalent daily dose. In conclusion, significant differences in serum progesterone concentration exist between different vaginal progesterone products and dosing regimens, which must be taken into account when performing HRT-FET.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"50 5","pages":"Article 104736"},"PeriodicalIF":3.7,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The complementary seminovaginal microbiome in health and disease","authors":"Nerea M. Molina ,&nbsp;Analuce Canha-Gouveia ,&nbsp;Irene Leonés-Baños ,&nbsp;Alberto Sola-Leyva ,&nbsp;Eva Vargas ,&nbsp;Susana Ruíz-Durán ,&nbsp;Celia M. Tenorio ,&nbsp;Ana Clavero-Gilabert ,&nbsp;Reet Mändar ,&nbsp;Signe Altmäe","doi":"10.1016/j.rbmo.2024.104707","DOIUrl":"10.1016/j.rbmo.2024.104707","url":null,"abstract":"<div><div>Infertility, adverse pregnancy outcomes and genital infections are global concerns. The reproductive tract microbiome appears to play a crucial role in the physiology of both the female and male reproductive tracts. Despite the presence of thousands of microbes in body fluids shared during unprotected sexual intercourse, they have traditionally been studied separately, with greater emphasis on the female (mostly vaginal) microbiome, and the interaction between these microbiomes in a sexually active couple has been overlooked. This review introduces the concept of the ‘seminovaginal microbiome’ – the collective microbiota of both partners, transferred and shared during sexual interaction. By synthesizing the existing body of next-generation sequencing-based literature, this review establishes the first holistic view of how these microbiomes interact, influence reproductive health and affect assisted reproductive technique outcomes, as well as the occurrence of microbe-associated diseases such as sexually transmitted infections, prostatitis, bacterial vaginosis and candidiasis. Additionally, the microbial interplay in homosexual couples and transgender individuals is discussed.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"50 5","pages":"Article 104707"},"PeriodicalIF":3.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sociodemographic profile of women seeking elective egg freezing when financed by the public healthcare system","authors":"Mariam Chehimi ,&nbsp;Angèle Boursier ,&nbsp;Valérie Lefebvre-Khalil ,&nbsp;Christine Decanter ,&nbsp;Laura Keller ,&nbsp;Valentyn Fournier ,&nbsp;Anne-Laure Barbotin","doi":"10.1016/j.rbmo.2024.104705","DOIUrl":"10.1016/j.rbmo.2024.104705","url":null,"abstract":"<div><h3>Research question</h3><div>What is the sociodemographic profile of women requesting elective egg freezing (EEF) in France, in the context of full health insurance coverage for this procedure since 2021?</div></div><div><h3>Design</h3><div>A cross-sectional prospective survey study was conducted from November 2022 to April 2024, exploring sociodemographic profile, motivations, communication about the procedure in France, intentions to request sperm donation, and attitudes in the case of non-use of stored oocytes. Hierarchical cluster analysis was used to identify subgroups of women based on their answers.</div></div><div><h3>Results</h3><div>Women requesting EEF had a median age of 35.35 (IQR 33.85–36.08) years, were single (72.2%), and resided in urban areas (92.2%). The majority belonged to a high socioprofessional category (68.3%). Nearly two-thirds (64.4%) of these women stated that they would not have considered EEF if it had not been covered by the national healthcare system. The main reason for applying for EEF was the absence of a suitable partner (64%). Regarding future parenting plans, 8.9% of women had registered for sperm donation in addition to EEF. In the case of non-use of their stored oocytes, more than half of the women (58%) would consider donating them (48% to a couple exclusively, 10% to research or a couple). A significant proportion of women (26.1%) were in a heterosexual relationship at the time of EEF.</div></div><div><h3>Conclusion</h3><div>To the authors’ knowledge, this is the first study to show that full insurance coverage of EEF has little impact on the sociodemographic profile of women requesting it in France compared with similar data published in studies from countries in which patients bear the cost of EEF.</div></div>","PeriodicalId":21134,"journal":{"name":"Reproductive biomedicine online","volume":"50 5","pages":"Article 104705"},"PeriodicalIF":3.7,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143734750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}